Archive · 17 Sep 2025
Nimesulide Sales Stagnate Amid Safety Warnings & Combination Therapy Rise
Nimesulide, a painkiller used in India, is facing new rules.
The government is making sure people use it carefully because of potential liver problems.
All Nimesulide packages must now have a warning.
Doctors are told to use it only after trying other medicines.
Also, it cannot be used for kids under 12.
While plain Nimesulide sales are flat, medicines that mix Nimesulide with other ingredients are becoming more popular.
This is due to a growing preference for combo medications which can also deal with the consumers' symptoms.
Sales of plain Nimesulide have stagnated, while combination therapies are growing.
The government mandated a 'Box Warning' for Nimesulide due to safety concerns.
Nimesulide is now recommended as a second-line treatment in India.
Nimesulide is not to be used by pregnant, lactating women, or those with kidney/liver issues.
A recent study reported that Nimesulide is effective in reducing fever and pain in adults.
- Who
- Indian drug manufacturers, regulators, and consumers
- What
- Stagnation in plain Nimesulide sales, and new regulations
- When
- August 2021 - August 2025, with a recent government mandate
- Where
- India
- Why
- Safety concerns and preference for combination therapies.
- Drug Name
- Nimesulide
- Sales Trend
- Stagnant for plain Nimesulide; increasing for combination therapies
- Box Warning
- Mandatory on all Nimesulide products
- Age Restriction
- Prohibited for children under 12
- Concerns
- Potential liver toxicity
- Recommended Use
- Second-line therapy only
